Democratic Defection on Build Back Better Act Sets Back Drive to Lower Drug Prices

U.S. Sen. Joe Manchin’s (D-W.Va.) rejection of his fellow Democrats’ Build Back Better (BBB) policy agenda left its drug pricing section dead in the water.

West Virginia U.S. Sen. Joe Manchin’s rejection Sunday of his fellow Democrats’ Build Back Better (BBB) policy agenda left its drug pricing section dead in the water.

Manchin said of the BBA bill on Dec. 19, “I cannot vote to

Read More »

House Committee Releases Report With 340B Implications

The U.S. House Oversight and Reform Committee has issued a blistering report about drug industry pricing and business practices.

The U.S. House Oversight and Reform Committee issued a blistering report late last week accusing brand pharmaceutical manufacturers of systematically jacking up prices on their drugs in the United States.

Pharmaceutical Research and Manufacturers of America (PhRMA) called it a

Read More »

Senate Finance Committee’s New Drug Pricing Text Includes a New 340B Provision

The U.S. Senate Finance Committee’s latest drug pricing legislation includes 340B language not seen before in earlier House and Senate versions.

The U.S. Senate Finance Committee’s latest drug pricing legislation includes language, not seen before in earlier House and Senate versions, about denying 340B covered entities’ access to government-negotiated lower prices on drugs covered under Medicare.

The committee released the

Read More »

House Panel Holding What Might be Last Hearing of its Drug Pricing Investigation

The U.S. House Oversight and Reform Committee is holding a hearing to review the findings of its investigation into drug industry pricing and business practices.

The Democratic-led U.S. House Oversight and Reform Committee is holding a hearing this Thursday to review the findings of its nearly three-year investigation into drug industry pricing and business practices.

The Dec. 9 hearing starts at 10:30 a.m. Eastern. It’s

Read More »

U.S. House GOP Conference Chair Stefanik Backs Protecting 340B Hospitals from Losing Eligibility During Pandemic

U.S. House GOP Conference Chair Elise Stefanik (N.Y.) is backing a bill to protect hospitals from losing their 340B eligibility due to pandemic-related changes in patient and payer mix.

Elise Stefanik, the third highest-ranking Republican in the U.S. House, is backing a bill to protect hospitals from losing their 340B eligibility due to pandemic-related changes in patient and payer mix.

Stefanik (R-N.Y.) announced her co-sponsorship of Reps. Doris

Read More »

Peter Welch, Long-Time 340B Advocate in the U.S. House, Announces Run for Senate

U.S. Sen. Peter Welch (D-VT) introduced a Senate version of the 340B PATIENTS Act.

U.S. Rep. Peter Welch (D-Vt.), who has backed 340B covered entities in several policy battles, is running to succeed his fellow Democrat Patrick Leahy in the U.S. Senate.

Senate President Pro Tempore Leahy, 81, announced on Nov. 15 that he

Read More »

340B Report Publisher and CEO: Expect Congress to Act on 340B Contract Pharmacy Before Midterm Elections

Expect Congress to end the fight over contract pharmacy before the 2022 midterm elections, 340B Report Publisher and CEO Ted Slafsky predicts in his latest column for Omnicell.

After five major court decisions on the 340B contract pharmacy standoff and no quick resolution in sight, expect Congress to end the fight over contract pharmacy before the 2022 midterm elections, 340B Report Publisher and CEO Ted Slafsky predicts in

Read More »

After Successful House Vote, Attention Turns to Senate on Major Drug Pricing Bill

The Senate version of the 340B PATIENTS Act faces hurdles to passage despite broad support from provider groups.

Congressional debate over lowering drug prices has shifted to the U.S. Senate following House passage of the $1.75 trillion Build Back Better social spending bill on Friday.

Congress has been on break this week for the Thanksgiving holiday. It returns

Read More »

GOP Congressman Slams PBMs for Taking Away Safety Net Providers’ 340B Savings

Rep. Jake La Turner (R-Kan.) said yesterday he is concerned about PBMs "pickpocketing" health centers and other safety net providers' 340B savings.

A Kansas Republican congressman said on Capitol Hill yesterday that pharmacy benefit managers (PBMs) are taking away health centers and other safety net providers’ 340B savings and driving up their costs.

340B health centers and other providers “are reporting that

Read More »

340B Providers Appear to Escape Bullet as Negotiations Continue on Build Back Better Bill’s Drug Pricing Provisions

The Build Back Better bill is still bogged down by infighting among Democrats, and its numerous drug pricing provisions will likely undergo changes prior to any votes.

Although Congress was able to pass a $1.2 trillion bipartisan infrastructure package last week, the nearly $1.8 trillion Build Back Better bill remains bogged down by infighting among Democrats. Its numerous drug pricing provisions will likely undergo changes prior to

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live